Description

Cabometyx (Cabozantinib)

Overview

Cabometyx is the brand name for cabozantinib, an oral targeted cancer therapy classified as a tyrosine kinase inhibitor (TKI). It works by blocking multiple receptor tyrosine kinases involved in tumor growth, angiogenesis (formation of new blood vessels), metastasis, and cancer progression. By inhibiting these signaling pathways, Cabometyx helps slow or stop the growth and spread of cancer cells.

Indications

Cabometyx is approved for the treatment of several advanced cancers, including:

• Advanced renal cell carcinoma (RCC) as monotherapy.
• First-line treatment of advanced RCC in combination with nivolumab.
• Hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
• Locally advanced or metastatic differentiated thyroid cancer (DTC) that is refractory to radioactive iodine or ineligible for radioactive iodine therapy.
• Previously treated, unresectable, locally advanced, or metastatic pancreatic neuroendocrine tumors (pNET).
• Previously treated, unresectable, locally advanced, or metastatic extra-pancreatic neuroendocrine tumors (epNET).

Mechanism of Action

Cabozantinib inhibits multiple receptor tyrosine kinases, including VEGFR, MET, and AXL. These pathways play important roles in tumor angiogenesis, tumor cell proliferation, invasion, and metastasis. By targeting these receptors, Cabometyx reduces blood supply to tumors and suppresses cancer cell growth and survival.

Administration

Cabometyx is administered orally once daily. The tablets should be taken on an empty stomach, at least one hour before or two hours after eating. Tablets should be swallowed whole and not crushed, chewed, or split. Dosage may vary depending on the cancer type, treatment regimen, and patient-specific factors.

Common Side Effects

The most frequently reported adverse reactions include:

• Diarrhea
• Fatigue
• Decreased appetite
• Nausea
• Weight loss
• Hypertension
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Stomatitis (mouth sores)
• Vomiting
• Constipation

Healthcare providers may adjust the dose or temporarily discontinue treatment if significant adverse effects occur.

Safety Considerations

Patients receiving Cabometyx should be monitored for serious adverse events, including hemorrhage, gastrointestinal perforation, fistula formation, hypertension, thromboembolic events, impaired wound healing, and cardiac complications. Treatment should generally be stopped before major surgery and resumed only after adequate wound healing.

Clinical Significance

Cabometyx has demonstrated significant clinical benefits in multiple cancer types by improving progression-free survival and, in some indications, overall survival. It has become an important treatment option for patients with advanced kidney cancer, liver cancer, thyroid cancer, and neuroendocrine tumors.

Conclusion

Cabometyx (cabozantinib) is a multi-targeted tyrosine kinase inhibitor used in the treatment of several advanced malignancies. Through inhibition of pathways involved in tumor growth and angiogenesis, it provides an effective therapeutic option for patients with difficult-to-treat cancers while requiring careful monitoring for potential adverse effects.